TY - JOUR
T1 - Induction of ovulation with combined human gonadotropins and dexamethasone in women with polycystic ovarian disease
AU - Evron, S.
AU - Navot, D.
AU - Laufer, N.
AU - Diamant, Y. Z.
N1 - Funding Information:
Received December 20, 1982; revised and accepted April 27, 1983. *Supported in part by the Joint Research Fund ofHadassah University Hospital and The Hebrew University, Jerusalem, Israel. tDepartment of Obstetrics and Gynecology, Hadassah University Hospital. :j:Reprint requests: Shmuel Evron, M.D., Department of Obstetrics and Gynecology, Hadassah University Hospital, P.O.B. 12000, Jerusalem, Israel. §Department of Obstetrics and Gynecology, Bikur Cholim Hospital.
PY - 1983
Y1 - 1983
N2 - A combined treatment of human menopausal gonadotropin (hMG), human chorionic gonadotropin (hCG), and dexamethasone was administered to 27 infertile patients with polycystic ovarian disease who failed to conceive with clomiphene citrate and hMG-hCG alone. Twenty-two (81%) of the patients ovulated according to basal body temperature and progesterone values, and 20 (74%) conceived during one to four treatment cycles. Fifteen (74%) pregnancies terminated in live full-term deliveries (14 singletons and 1 set of twins), and 5 (25%) have terminated in first-trimester abortions. Only one of the treatment cycles was complicated by moderate ovarian hyperstimulation. The average hMG dose required for the induction of ovulation was significantly reduced from 25 ampules with hMG-hCG alone to 18 ampules under the combined treatment (P < 0.01). The combination of hMG-hCG and dexamethasone is an additional, safe, and effective nonsurgical treatment for women with polycystic ovarian disease who have failed to respond to an hMG-hCG regimen alone.
AB - A combined treatment of human menopausal gonadotropin (hMG), human chorionic gonadotropin (hCG), and dexamethasone was administered to 27 infertile patients with polycystic ovarian disease who failed to conceive with clomiphene citrate and hMG-hCG alone. Twenty-two (81%) of the patients ovulated according to basal body temperature and progesterone values, and 20 (74%) conceived during one to four treatment cycles. Fifteen (74%) pregnancies terminated in live full-term deliveries (14 singletons and 1 set of twins), and 5 (25%) have terminated in first-trimester abortions. Only one of the treatment cycles was complicated by moderate ovarian hyperstimulation. The average hMG dose required for the induction of ovulation was significantly reduced from 25 ampules with hMG-hCG alone to 18 ampules under the combined treatment (P < 0.01). The combination of hMG-hCG and dexamethasone is an additional, safe, and effective nonsurgical treatment for women with polycystic ovarian disease who have failed to respond to an hMG-hCG regimen alone.
UR - http://www.scopus.com/inward/record.url?scp=0020602675&partnerID=8YFLogxK
U2 - 10.1016/S0015-0282(16)47234-1
DO - 10.1016/S0015-0282(16)47234-1
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0020602675
SN - 0015-0282
VL - 40
SP - 183
EP - 186
JO - Fertility and Sterility
JF - Fertility and Sterility
IS - 2
ER -